Background
A foundation for continuous quality improvement is to measure and compare care across practices and providers to translate successful management strategies to others [1] . Performance measurement has traditionally relied on routinely collected clinical information such as rates of hospital readmission, infections, procedural complications, survival, or laboratory values. But the ultimate impact on outcomes experienced by patients, such as symptoms, functional status, and health-related quality of life, have rarely been assessed.
Collection and analysis of patient-reported outcome (PRO) measures is increasingly considered a standard approach for evaluating these experiences [2] [3] [4] [5] . A PRO is defined as information about the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else [3] . A patient-reported outcome measure (PROM) is a questionnaire used to elicit information directly from respondents. Inclusion of patients' direct reports about how they feel and function in quality assessment programs through the use of patient-reported outcome-based performance measures (PRO-PMs), and particularly in accountability and value-based payment initiatives, would increase the patient-centeredness of these activities [6] [7] [8] . PRO measurement is already common in clinical trials and is of rising interest in comparative effectiveness research, routine clinical practice, and electronic medical record systems [9] [10] [11] [12] [13] [14] .
Beyond patient-centeredness, there are additional rationales to include PROs in performance measurement. Recent data suggest that patients' self-reported symptoms and health status are associated with the use of medical services (e.g., emergency room visits and hospitalizations), costs, outpatient medication compliance, and survival [15] [16] [17] [18] . The process of patient selfreporting itself can improve symptom management, quality of life, communication, and satisfaction with care [19] [20] [21] [22] . Moreover, symptoms and functional status impairment are far more common than serious complications of treatment, such as hospitalizations or death [23] . As the ultimate end users of services, patients selecting a treatment or provider may have interest in outcomes based on previous reports of patients like themselves.
There is currently limited understanding in the PRO methodology community about performance measurement procedures, and a similarly limited understanding in the performance measurement community about methodological challenges involved with developing, administering, and analyzing PRO data. Therefore, there is a need for a practical blueprint to bring these two fields together and describe methodological best practices for developing, testing, implementing, and interpreting PRO performance measures that can be used as criteria by measure developers and credentialing organizations to evaluate candidate measures.
Methods

Technical Expert Panel
The American Medical Association-convened Physician Consortium for Performance Improvement, which has overseen the specification and testing of health care performance measures in the United States for more than 10 years, assembled a Technical Expert Panel to develop methodological best practices for guiding the development and evaluation of PRO measures in performance evaluation. The panel consisted of experts in performance measurement, PROs, clinical research, health services research, as well as clinical practitioners and patient representatives (represented by the authors of this article). By design, the panel's focus was restricted to traditional domains measured by PROs, including symptoms, functional status, and health-related quality of life, and did not encompass patientreported health-related behaviors or satisfaction with care (sometimes referred to as patient-reported experience measures, e.g., patient perceptions of clinic wait times or staff attentiveness), which are related but distinct areas of measurement with a more extensive history in performance evaluation [24] [25] [26] [27] .
Environmental Scan
The panel first completed an environmental scan (including a structured literature review) of existing pertinent initiatives using PROs for quality assessment ("use cases"), and related methods guidance documents. The purpose of finding use cases was both to evaluate the current state of this field and to identify areas warranting best practice recommendations.
The literature review was initially conducted in January 2012 and updated in April 2013, via the PubMed electronic database consisting of two searches, the first focused on published reports of research using PROs to assess performance and the second focused on existing salient guidance documents. Search terms are listed in the Appendix in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2015.02.018.
Identified publication titles and abstracts were reviewed by two members of the panel and categorized independently as not relevant, maybe relevant, or relevant, with citations considered not relevant by both researchers eliminated and remaining citations presented to the panel for evaluation. Relevance was based on two required criteria: 1) elicitation of information about symptoms, functional status, or health-related quality of life directly from patients using PRO measures and 2) an objective of measuring or improving performance/quality of care delivery. Subsequent steps included assessment of the quality of each identified study and review of references to find additional potentially relevant articles.
The environmental scan also consisted of a Google search using permutations of the same terms, which were reviewed in real time for performance measurement initiatives using PROs, as well as existing PRO guidance documents. These searches were supplemented by results of reports contracted by the PatientCentered Outcomes Research Institute, which are publicly available [28, 29] , and distribution of an e-mail inquiry to an assembled list of investigators involved in PRO research and performance measurement research.
Identified use cases were reviewed by the panel-with direct communication with investigators whenever possible-to identify the design and measures used for each initiative. "Key findings" were assembled for each use case on the basis of published data and investigator communication, encompassing the a priori selected areas of sample size, recruitment and response/retention rates, project duration, and observed results. "Lessons learned" were assembled encompassing the a priori selected areas of bias and adjustment, compliance and missing data, and feasibility.
Results
Use Cases and Guidance Documents
Of 21,342 titles identified by the literature search, 6 publications were identified that described initiatives in which PROs were used in performance evaluation [30] [31] [32] [33] [34] [35] . Three additional relevant initiatives were identified via the Google search [36] [37] [38] and an additional four via the e-mail distribution [39] [40] [41] [42] . These 13 use cases are described below and in Table 1 , including key findings and lessons learned.
A classification challenge in identifying use cases is that there are many initiatives using PROs in clinical practice, in observational research/comparative effectiveness research, or in integrating PROs with electronic health records. Although these projects include closely related design elements and can be instructive, they are not performance-improvement oriented per se and were therefore excluded from the analysis. Conversely, there are programs that incorporate measures in which patient experiences such as pain are expected to be elicited by providers from patients and documented, but do not require a specific PRO measure to be used. To be included in the use cases, an example had to include not only the administration of PRO measures but also a research design intended to measure performance. It is recognized that other use cases exist that were not included, and the panel felt that the identified cases provided a sufficient basis for developing best practices.
Beyond the use cases, 10 PRO methodological guidance documents pertaining to other health care areas were identified and considered by the panel in establishing best practices [3] [4] [5] [43] [44] [45] [46] [47] [48] . These documents encompass both regulatory and nonregulatory uses of PRO measures largely in the clinical research context.
Analysis of Use Cases
Overall, the use cases and guidance documents underscore that PROs are appropriate when information sought is best known by the patient, for example, symptoms. Outcomes and analysis results should be important and meaningful to patients in a prespecified target population in a prespecified context of use. Similarly, measured outcomes should be sensitive to changes in clinical practice and relevant to clinicians and other decision makers (i.e., actionable). If an outcome cannot be improved by a change in practice, it is likely not appropriate for performance measurement. Is there a plan to maximize recruitment and response rates (e.g., backup data collection plan for nonrespondents)?
Is proxy or surrogate reporting considered allowable?
Is there a plan to accurately identify patients in the target population and calculate the denominator (i.e., number of people who were asked to complete the measure)?
Feasibility continued on next page
The importance of pilot work to evaluate response rates, sensitivity to within-and between-practice variations, appropriate unit(s) of analysis, and barriers to implementation, as well as continued evaluation of programs to improve implementation strategies, is also emphasized.
Use of measures with well-established psychometric properties is a common theme in the identified use cases and particularly in guidance documents, including qualitative and quantitative data to establish that patients in a target population understand terms and that terms map to underlying outcomes of interest; construct validity; reliability; sensitivity to change over time; appropriate recall period; meaningfulness of score thresholds and changes to patients; and adequacy of cultural, linguistic, and mode adaptation as needed.
The availability and use of methods to optimize response rates and minimize missing data is an almost universal theme, with approaches to optimize response rates including centralized data collection, reminder mechanisms, mandatory collection of information in practices (rather than voluntary or subpopulation collection), partnership with providers and communities, and use of proxy/surrogate reporting.
Most use cases include a risk/case-mix adjustment strategy. In some instances, adjustment for response rates is considered in analyses to avoid response bias; that is, patients with worse outcomes are less likely to return a questionnaire, so those providers who are most vigilant about obtaining follow-up questionnaires may recover a higher proportion of responses from sicker individuals with worse outcomes, making their results look worse if analyses are unadjusted.
An a priori plan for data analysis, interpretation, and dissemination is emphasized. This includes a plan for handling missing data using imputation methods because patient-reported data are often missing not at random [49] . Other issues include dealing with multiple end points/comparisons, measuring cross-sectional differences versus changes over time, adequacy of sample size and potential overpowering, and consideration of outliers in analyses. Most of these issues are not unique to PRO-based analyses.
Best Practice Recommendations
Five a priori areas of review guided the panel in analyzing use cases and guidelines to extract best practices that facilitate the development of clinically meaningful and scientifically robust performance measures: selection of outcomes, development/ selection of metrics, implementation, analysis, and reporting/ dissemination. This analysis yielded nine best practices that are presented in Table 2 along with specific questions that can be considered to determine whether a measure abides by the recommendations. Panel agreement was unanimous on each; refinements were made on the basis of public comment (described below). The best practices were approved by the Physician Consortium for Performance Improvement Measures Implementation and Informatics Committee.
The panel concluded that a PRO measure should be considered within the proposed context of use and implementation strategy. Therefore, information about these should be provided with candidate measures. It is acknowledged that not all the 
information specified in the table will be available or appropriate for all approaches, especially in these early days of developing and testing PRO performance measures. But the considerations should be addressed, and some may be tested within early implementation or pilot work. The panel concluded that an actionable PRO measure is one that can identify patients for whom changes in care might be warranted and detects changes in outcomes after treatment. Demonstration of this capacity is advisable before widespread implementation. Because the use of PROs in performance evaluation has been uncommon in the past, it is acknowledged that research in other related contexts may be relied upon initially for such evidence, such as use of a measure in clinical trials or comparative effectiveness research. When adapting an existing PROM for use in performance measurement (e.g., a measure initially developed for use in clinical research), it should be considered whether it 1) assesses outcomes that are meaningful in the population/context of interest and are actionable; 2) has been found understandable to patients in qualitative assessments; 3) demonstrates validity, reliability, and responsiveness; and 4) is feasible to implement (e.g., is not excessively lengthy, has available language translations if necessary, and can be administered electronically if necessary). Specific approaches for adapting PROMs into PRO-PMs have previously been described by the National Quality Forum (NQF), as well as details about the distinctions between PROs, PROMs, and PRO-PMs [50] .
The goal of measuring PROs and rewarding performance on the basis of PROs is to encourage clinicians and organizations to adopt procedures that improve outcomes experienced by patients. Accurate measurement of PROs will be hindered if variation in performance among providers primarily reflects differences in the underlying populations served and adjustment methods are not used. Quantifying changes in scores over time compared with baseline, rather than relying on cross-sectional analyses, allows patients to serve as their own controls and accounts for baseline health status. It is acknowledged that risk-adjustment approaches may be refined over time in a particular program and that risk adjustment may be deemed unnecessary in some contexts (which should be demonstrated with empiric evidence). A practical example of how the best practices may be used to develop a measure is provided in Table 3 .
Harmonization with NQF White Paper and Public Comment
During the period of development of these best practices, the NQF produced a white paper outlining a pathway for PRO-PMs [50, 51] . Because of the importance of the NQF as the major US organization for endorsing performance measures, it was considered important by the panel to harmonize the panel's and the NQF's efforts. Therefore, the panel's best practices and the NQF pathway were mapped to each other in a table to assist measure developers who may wish to understand how the different recommendations relate to each other (Table 2) .
A draft of the best practice recommendations was posted on the Physician Consortium for Performance Improvement Web site during a 3-week public comment period. Input was elicited for each individual recommendation, and overall. The public comment process yielded feedback from 15 national and international organizations. No major substantive changes were suggested. Each comment was reviewed in a panel meeting with individual responses generated, and alterations to the recommendations were made on the basis of panel consensus.
Purposes for Using PRO-PMs
On the basis of the use cases, the panel identified five purposes for which PRO measures may be used in performance evaluation (Table 4 ). An underlying premise is that PROs should be used when information sought is best known by the patient, for example, symptoms. This information can be used along with information from other sources, such as the medical chart. The table provides illustrations of how each of the five purposes could be pursued in specific contexts of use. These purposes are not mutually exclusive, and can be addressed together in a given assessment program, sometimes within the same data collection strategy.
Discussion
This article presents use cases of PRO-PM development and implementation that along with several identified guidance documents informed the development of best practices. A group of purposes for developing PRO-PMs and using the best practices is also presented to guide measure developers in thinking about how PROs might best be used in a given context. A large network of community oncology practices is interested in understanding differences between practices in postchemotherapy nausea control as a potential quality measure. The rationale for this measure is published crosssectional data about rates of nausea, and about variable compliance with published antiemetic guidelines (best practice 1). The purpose of the measure is to understand whether there are variable rates of nausea control between practices that might be improved through educational programs or feedback to providers (best practice 2). An existing nausea measure from the National Cancer Institute's (NCI's) PRO-CTCAE symptom library is selected on the basis of published qualitative and quantitative data in a similar community practice context, providing evidence that the measure evaluates a symptom that is important and meaningful to patients, with acceptable validity and reliability. Relevant permissions from the NCI are obtained (best practices 3 and 4). A multidisciplinary planning panel, including patient representatives, identifies the pertinent population as patients receiving moderately or highly emetogenic chemotherapy according to existing criteria (best practice 2). It is determined on the basis of a literature review to use an automated telephone system (IVRS) with live interviewer backup to assess symptoms at baseline (and to collect baseline data for risk adjustment), as well as daily following chemotherapy for 7 d (best practice 5). The proportion of patients experiencing moderate and severe nausea at more than one time point following chemotherapy at the practice level is chosen as the a priori primary end point, with risk adjustment for age, comorbidities, stage of cancer, number of prior lines of chemotherapy, time since diagnosis, baseline quality of life (via a PROMIS single measure), baseline nausea, and comorbidities (best practices 6 and 7). Exploratory analyses will be used to evaluate alternative end points in the analysis phase and refine the risk adjustment model. A sample size is determined by a biostatistician on the basis of published effect sizes for similar patients, accounting for anticipated missing data and attrition (best practice 6). Results will be fed back to practices with a planned onsite educational program offered to sites with lower performance (best practice 8). Follow-up assessment of practices following educational programs is planned to assess the impact of the programs, in addition to eliciting provider feedback about the program (best practice 9).
IVRS, interactive voice response system; PRO-CTCAE, PatientReported Outcomes version of the Common Terminology Criteria for Adverse Events; PROMIS, Patient-Reported Outcomes Measurement Information System.
A key underlying premise of the best practices is that evaluation of a proposed PRO performance measure warrants more than simply understanding whether the measure is valid and reliableit requires an overall measurement strategy that takes into account the intended context of use, population, and meaningfulness to patients. It is acknowledged that at the current time, there is limited experience with these approaches, and the best practices are anticipated to evolve as evidence accumulates. It is also recognized that overly stringent standards should not hinder the endorsement of projects that may enrich knowledge and advance this area. Not all best practices will be abided by, or are appropriate, in all proposals.
Among the five identified "purposes" for collecting PRO data in performance measurement in Table 4 , the fifth, "Assess use of patient-reported outcomes to enhance clinical practice," is perhaps the most novel. Although there is increasing interest in routinely collecting PRO measures to enhance clinical management, this is still not standard practice [9, 12, 14] . Many operational questions remain however: how should this information optimally be collected (paper vs. electronic; in waiting rooms vs. from home between visits); when should initial and follow-up assessments be conducted; who should review this information and when; what specific information should be collected; should clinical actions resulting from this information be tracked? These questions merit future research, and approaches are expected to vary depending on the intended context of use of a measure.
Moving forward, there are a number of challenges, some which are inherent to PRO measurement, and some that apply to performance measurement more broadly. Maximizing recruitment and response rates (particularly from the sickest and busiest patients) and analyzing missing data are perennial challenges in PRO assessment [49] . Poor performance may be underdetected if ill patients systematically do not self-report, and sites that more effectively encourage sicker patients to return questionnaires may appear to have worse quality, unless analyses are adjusted for response bias. An additional challenge is identifying formats for reporting findings in a manner that is accessible, interpretable, meaningful, and actionable across stakeholders [52] .
Conclusions
Enthusiasm to elicit the patient perspective in performance evaluation is evolving within a broader context of patientcenteredness in health care delivery, research, and policy [8] . The overall goal of developing best practices for PRO-PMs is to provide a framework and context-appropriate specifications for supporting the development of patient-centered performance measurement strategies. It is the hope of the authors that these best practices will encourage future development of rigorous approaches that help better characterize the impact of care on the patient experience, and enable mechanisms for improving that experience across populations.
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